BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:WD-890 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of WD-890\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07672561-1865@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:WD-890: Phase 3 readout est. (NCT07672561)
DESCRIPTION:WD-890\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomize
 d\, Double-Blind\, Placebo-Controlled Phase Ⅲ Study to Evaluate the Effi
 cacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe 
 Plaque Psoriasis\nEstimated primary completion: 30 November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/wd-890#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07672561
URL:https://assetmemo.bio/drug/wd-890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
